Transferring Healt Big Data within the European Legal Framework: What Role for National Healthcare Services? by D. Golinelli et al.
488 
Transferring Health Big Data within the 
European Legal Framework: What Role for 
National Healthcare Services?
Davide Golinelli, Fabrizio Toscano, Andrea Bucci and Gherardo Carullo*
The main objective of this article is to describe the legal principles governing the selection by 
European public authorities, such as National Health Services (NHS) of third parties, when 
entering into agreements for the transfer of health data. According to Directive 2003/98/EC, 
and in light of the provisions of the Treaties of the European Union, the choice as to how a 
public authority makes its data available to third parties needs to be transparent, non-
discriminatory and may not in any case benefit a specific company at the expense of others. 
For this reason, we maintain that a hypothetical agreement by which a public authority grants 
exclusive access to a large amount of health data to a private company selected with non-
transparent criteria appears highly questionable. We advocate that the NHS should adopt more 
appropriate data policies aimed at promoting the sustainability of the NHS, following the legal 
framework analysed in this article.
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INTRODUCTION
The term “Big Data” (BD) in health care refers to volumes of large, complex, linkable information1, that 
can be defined as routinely or automatically collected datasets, which are electronically captured and 
stored2. It is re-usable in the sense of multipurpose data3 and comprises the fusion and connection of 
existing databases for the purpose of improving health and health system performance.4
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From an economic point of view, global spending on BD technologies surpassed $US57 billion in 
2017 and will increase by at least 10% per year up to 2020.5 Collecting data is easier than ever and 
implementing tools to work with BD has also become much more accessible.
Through BD-processing software, it is possible to group huge and complex information, which can be 
analysed by few operators. This represents an opportunity and an important tool for health care. As a 
matter of fact, in this sector BD applications can target many different fields (individual and personalised 
care, clinical research, epidemiology, health services research, etc) through prospective data monitoring 
or retrospective data analysis.6 These innovative tools have the potential to help to improve health care 
by providing insights into the causes and outcomes of diseases, better drug targets for precision medicine 
and enhanced disease prediction and prevention.7
When considering the use of BD in health care it is crucial to understand what the sources of data and the 
processes behind their collection are.8 There are many potential sources of data related to health care9: 
routinely recorded health data, pharmaceutical data, genomic data, wearable devices, social media and 
internet cookies, and the internet of things, just to name a few.10 This vast number of data sources reflects 
the numerous players involved in the BD challenge in health care (Table 1) and may entail a potential 
conflict between them. Two recent events suggest the need for a deeper analysis of the connection 
between different BD players and national health care services (NHS).
TABLE 1. Big Data players in health care: National health care service; IBM: International 
Business Machines Corporation.
Category Players
Traditional players Pharmaceutical firms, Hospitals and Medical-technology companies
Forced players Health insurers, Pharmacy-benefit managers, and Single-payer national health care services such as Britain NHS or Italian Servizio Sanitario Nazionale.
New players Amazon, IBM, Google, Apple, etc.
In the United Kingdom, Alphabet Inc. (the parent company of Google Inc.), through its British-based 
artificial intelligence subsidiary (DeepMind Technologies Limited, DeepMind), reached an agreement 
with the Royal Free London NHS Foundation Trust (Royal Free) between July 2015 and October 2016. 
Royal Free agreed to transfer to DeepMind identifiable patient records, without obtaining the prior 
explicit consent of patients, so that the latter may use such data for developing a clinical alert app for 
kidney injury.
Julia Powles and Hal Hodson have highlighted several critical aspects of the agreement.11 They have 
concluded that existing institutional and regulatory responses are insufficiently robust and agile to 
respond properly to the challenges presented by data politics and the rise of algorithmic tools in health 
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care. Indeed, in July 2017 the United Kingdom data protection authority ruled that DeepMind was 
unlawfully given the health records of 1.6 million patients.12
In Italy, in March 2016 IBM announced plans to launch its first Watson Health European Center of 
Excellence in Milan, near the Human Technopole Italy 2040 research campus. In doing so, IBM would 
financially support the Italian government initiative to establish an international hub for the advancement of 
genomics, BD, ageing and nutrition.13 At the time of writing, the details of the agreement remain unknown.
According to the available information, it appears that the economic investment by IBM would be 
subordinated to the acquisition of Lombardia region residents’ health data (10,019,166 population in 
2014), the so-called “Protected Health Information”, including “health care-related data”, “personal 
clinical health records” and “nominal or anonymous fiscal information”.14
The outcome of the agreement could represent both an opportunity and a risk. Hypothetically, if the 
tools developed by IBM are integrated into the Italian NHS, in a way that is economically viable and 
favourable for the latter, there could indeed be mutual benefits. However, if the divergent interests of 
IBM and of the Italian NHS prevent such a positive result, considering the different mission of the two 
players, critical health data may be exposed without any actual benefit for Lombardia region residents.
PERSPECTIVE AND AIM OF THE ARTICLE
The examples of IBM/Italy and DeepMind/United Kingdom bring to light the need for the NHS – and for 
all the subjects involved – to take into due consideration the legal framework within which agreements 
on the transfer and re-use of health data can be entered upon.
For this reason, the main objective of this article is to describe the legal principles governing the selection 
by European public authorities (such as NHS) of third parties when entering into agreements for the 
transfer of health data.
Having defined such legal principles, the article discusses the role of the NHS in the challenge of BD 
exploitation. The need for updated, adequate and innovative data policies is a very current topic, and 
the debate on data-related processes and their lifecycle (Figure 1), particularly in health care, is intense. 
This phenomenon is well evidenced by the relevance of health data in Regulation  2016/679/EU on 
the protection of personal data (GDPR). Several provisions of the GDPR are aimed at informing and 
regulating policies on the use of health data.15 Given the limits established by the GDPR for processing 
health data, this article  takes for granted that data can be transferred to third parties only insofar as 
permitted by privacy regulations. For this reason, aspects regulated by the GDPR (eg data subjects’ 
consent, anonymisation, data safety, etc) will not be considered. The contribution of the article  is to 
highlight the further – and less obvious – legal provisions that regulate the selection of third parties to 
whom health data is to be transferred. In other words, the article focuses on the second phase of the 
data lifecycle (Figure 1), the one in which public authorities (ie data owners, such as the NHS) are in a 
position to decide whether or not to transfer their data to third parties.
FIGURE 1. Structure of the data lifecycle in health care, from data collection to use 
and/or transfer. NHS: National health care service; IOT: Internet of things.
13 IBM News, IBM Plans First Watson Health European Center of Excellence in Italy (31 March 2016) <https://www-03.ibm.com/
press/us/en/pressrelease/49436.wss>.
14  C Poggi, IBM Looking to Help  P.A. Enter New Digital Age, GM Cereda Says (9 September 2016) <http://www.italy24.
ilsole24ore.com/art/markets/2016-09-08/interview-cereda-ibm-113713.php?uuid=AD3cz2GB>.
15 See, eg, GDPR Art 9, para 2.
491
TRANSFER AND RE-USE OF DATA IN THE EUROPEAN LEGAL FRAMEWORK
Data held by public authorities are increasingly treated by European law as a raw material. Directive 
2003/98/EC (the Directive), provides a comprehensive regulation  of the re-use of public sector 
information (ie data), and in doing so its fifth recital expressly states that “public sector information is 
an important primary material for digital content products and services”.16 As provided by Art 1, para 1, 
the aim is to establish “a minimum set of rules governing the reuse and the practical means of facilitating 
re-use of existing documents held by public sector bodies of the Member States (MS)”.
According to Art 11, para 1, of the Directive, rules  for accessing documents shall be based on “fair, 
proportionate and non-discriminatory conditions”. Additionally, “contracts or other arrangements 
between the public sector bodies holding the documents and third parties shall not grant exclusive 
rights”. The second paragraph of Art 11 clarifies that exclusive agreements may be entered upon only 
if “necessary for the provision of a service in the public interest”. Recital 20 of the Directive explains 
that “this may be the case if no commercial publisher would publish the information without such an 
exclusive right”. In such a case, Art 11, para 2, provides that “the validity of the reason for granting such 
an exclusive right shall be subject to regular review, and shall, in any event, be reviewed every three 
years”. Moreover, the agreement “shall be transparent and made public”, to disclose the reasons which 
prompted the MS to adopt an exclusive deal.
However, the Directive applies only to data that MS had made accessible. As clarified by recital 9, the 
“Directive does not contain an obligation to allow re-use of documents”, and it is left to MS the choice 
of whether making data accessible. In other words, the Directive is applicable to the information held by 
public authorities only if it has been made accessible.
One could therefore doubt that the Directive applies to the agreement between the Italian Government 
and IBM, since the data being transferred to the latter have never been made accessible and have been 
granted solely to one company. In light of the spirit of the Directive, however, it must be maintained that 
the provisions regulating the limits within which exclusive agreements can be entered into must apply to 
exclusive agreements on the transfer of non-accessible data, like the one between the Italian Government 
and IBM.
This latter conclusion is indeed confirmed by the recent proposal for a revision of the Directive.17 
According to the explanatory memorandum by the European Commission, Art  12 of the proposal – 
corresponding to Art 11 in the current numbering18 – has been amended precisely “to specify that the 
16 Official Journal of the European Union, Directive 2003/98/EC of the European Parliament and of the Council (17 November 2003).
17 Proposal for a Directive of the European Parliament and of the Council on the re-use of public sector information, COM (2018) 
234 final (25 April 2018).
18 A new Art 10 of the proposal will shift subsequent numberings by one.
19 COM (2018) 234 final [11].
20 AG2R Prévoyance v Beaudout Père et Fils SARL (Court of Justice of the European Union, First Chamber, C-437/09, 3 March 
2011) [24]–[25].
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prohibition of exclusive arrangements shall also extend to such arrangements that do not expressly grant 
an exclusive right in the re-use of documents, but may lead to a situation where access is limited to one 
or very few re-users”.19
Regardless, even if the Directive were to be deemed not applicable, European law could still preclude an 
agreement like the one at issue. According to the case law of the European Court of Justice, “Article 101 
TFEU [Treaty on the Functioning of the European Union], read in conjunction with Article 4(3) EU, 
Member States are required not to introduce or maintain in force measures, whether legislative or 
regulatory, which may render ineffective the competition rules  applicable to undertakings” and that 
“under Article 106(1) TFEU […], in the case of public undertakings and undertakings to which Member 
States grant special or exclusive rights, Member States may neither enact nor maintain in force any 
measure contrary to the rules  contained in the Treaties, in particular to those rules  provided for in 
Article 18 TFEU and in Articles 101 TFEU to 109 TFEU, subject to Article 106(2) TFEU”.20
Under such case law, exclusive agreements between public authorities and undertakings can be entered 
into only within the limits of Art 106, para 2, TFEU, that is only if the company is “entrusted with the 
operation of services of general economic interest”, and only “insofar as it is necessary for performing 
the particular tasks assigned to them”.
Thus, it can be maintained that the choice on how a public authority, such as a NHS, makes available 
to third parties, for commercial purposes, its data – even if Directive 2003/98/EC were to be deemed 
not applicable – still needs to be transparent and non-discriminatory and may not in any case benefit a 
specific company at the expense of others.
In conclusion, an agreement by which a public authority grants exclusive access to a large number of 
health and personal data to a company selected with non-transparent criteria, appears highly questionable, 
whether under Directive 2003/98/EC, or in light of the fundamental principles and provisions of the EU 
Treaties.
WHAT ROLE FOR NATIONAL HEALTH CARE SERVICES?
In light of the legal framework highlighted in the previous paragraph, which in essence requires public 
authorities to act in a transparent and non-discriminatory manner when transferring health data, some 
questions may arise: What should be the role played by NHS in the BD challenge? What could be the 
risks related to BD exploitation and use?
A first consideration relates to the definition of NHS’ primary interest. In fact, both United Kingdom 
and Italian NHS, as virtually any NHS, aim at preserving their communities’ health. As a consequence, 
agreements such as those cited above can be deemed admissible only insofar as they are proved to be 
functional to an NHS’ interests.
Additionally, given that the economic sustainability of health care systems represents a concrete and 
current challenge for governments, every opportunity of self-financing should be taken into consideration. 
This includes properly assessing the possibility to benefit economically from a transparent and lawful 
transfer of data to third parties.
Single-payer NHSs should avoid acting passively – as in the cases of Italy and United Kingdom – and 
should act in a structured and consistent manner, by adopting stronger policies regarding health data 
creation, analysis and trade, contributing to their own financial sustainability. This can be done through 
the creation and/or implementation of NHS-owned data-platforms or data-warehouses, which can be 
made accessible to third parties for data transfer, re-use or analysis. Such an approach has been adopted, 
for example, in the United States by the Centers for Medicare and Medicaid Services, which has made 
available the claims data to researchers and analysts. The availability of claims data, moreover, has 
21  H Kharrazi et al, “Comparing Population-based Risk-stratification Model Performance Using Demographic, Diagnosis and 
Medication Data Extracted From Outpatient Electronic Health Records Versus Administrative Claims” (2017) 55 Medical Care 
789.
22 AB Frakt and SD Pizer, “The Promise and Perils of Big Data in Health Care” (2016) 22 American Journal of Managed Care 98.
493
generated a significant interest in the composition and implementation of the aforementioned claims 
data with the increasing adoption of electronic health records across the country. The combination of the 
two, in fact, constitutes an interesting set of BD not only to answer the increasingly value-based payment 
policies, but also to provide risk stratification and predictive modelling tools.21
Another consideration calls into question the quality of re-usable data and of its analysis. In fact, an 
ambiguous interpretation of BD can lead to potential risks for both individuals and populations and may 
consequently affect the sustainability of NHS. It could in particular lead to over- or under-use of health 
services and goods.
While gathering data is extremely important, BD players should evaluate how to use these new assets 
correctly and effectively.22 In fact, although new tools to create and analyze data are in the process of 
being implemented and perfected, letting data speak for themselves could lead to unrealistic relationships 
between outcomes and predictors, due to the so-called “spurious” correlation.
A real-world example of this misapprehension is provided by Google Flu Trends, which gives estimates 
of influenza spread by aggregating Google search queries. Google Flu Trends drastically overestimated 
2013 peak flu levels using flu-related Internet searches23.
All of the above suggests that one mandatory point in question in BD analysis is the need to interpret 
and/or map the proper dimensions of data correctly to extrapolate their meaning in specific settings and 
contexts, to protect the health of individuals and populations and to ensure the economic sustainability 
of NHS.24
CONCLUSIONS
This article illustrated the European legal framework within which BD players in the field of health care 
should work when they intend to co-operate with national public authorities.
According to the rules of national law, where public authorities decide to make their health or clinical 
data accessible, they will have to do so through transparent and predetermined criteria, to ensure that 
all economic operators are guaranteed equal access to data, without unjustified preferential or exclusive 
treatment. Moreover, NHS must favour the interests of patients, both as individuals and as part of a 
community. It follows that the legal criteria mentioned above should ensure that data are released in a 
manner consistent with the health protection mission pursued by NHS.
New thinking and a deeper debate about the role of NHS in the challenge of BD is needed to preserve 
the sustainability of NHS. This also raises the economic elements of the operation. National and local 
public authorities should take into due consideration the monetisation opportunities arising from the 
exploitation of BD, by adopting long-term structured data policies aimed at promoting the sustainability 
of national healthcare services, following the legal framework analyzed in this article.
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